These data suggest downregulation of lipolytic genes during CML disease progression, and that ATGL activity suppresses G0S2‐mediated apoptosis in the presence of imatinib. Here, PNPLA2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.